<?xml version="1.0" encoding="UTF-8"?>
<p id="Par43">Signal reporting from the MAH to NRAs should be proportionate to the information arising from the signal analysis. The IPVG proposes a risk-appropriate approach to signal reporting similar to recommendations made by the Swissmedic [
 <xref ref-type="bibr" rid="CR10">10</xref>] and that those signals that require in-market action (e.g. product information update, direct market communication, marketing authorisation suspension/revocation/withdrawal for safety reasons) should be notified to an NRA in line with Table 
 <xref rid="Tab4" ref-type="table">4</xref>.
</p>
